KRONライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	442 697
平均出来高	376 179
時価総額	60.10M
EPS	$0 ( 2024-03-20 )
次の収益日	( $-0.460 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.510
ATR14	$0.00300 (0.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-21	Olek Elizabeth A	Sell	7 368	Common Stock
2024-02-16	Olek Elizabeth A	Sell	0	Common Stock
2024-02-16	Olek Elizabeth A	Sell	89 120	Stock Option (Right to Buy)
2024-02-16	Olek Elizabeth A	Sell	145 795	Stock Option (Right to Buy)
2024-02-16	Olek Elizabeth A	Sell	87 500	Stock Option (Right to Buy)

INSIDER POWER
45.54
Last 97 transactions
Buy: 7 377 688 \| Sell: 1 665 671

ボリューム相関

長: -0.19 (neutral)

短: -0.66 (moderate negative)

Signal:(63.835) Neutral

Kronos Bio, Inc. 相関

10 最も正の相関
VVOS	0.892
PASG	0.886
SRTS	0.876
SGBX	0.876
FREQ	0.863
ATHE	0.858
CNDT	0.852
FOSL	0.846
KOD	0.841
VNET	0.84

10 最も負の相関
TYHT	-0.846
VERX	-0.827
BLCT	-0.81
HSTM	-0.81
XOG	-0.806

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Kronos Bio, Inc. 相関 - 通貨/商品

0.50
( neutral )

0.58
( weak )

0.00
( neutral )

-0.46
( neutral )

Kronos Bio, Inc. 財務諸表

Annual	2023
収益:	$6.29M
総利益:	$1.37M (21.82 %)
EPS:	$-1.950

FY	2023
収益:	$6.29M
総利益:	$1.37M (21.82 %)
EPS:	$-1.950

FY	2022
収益:	$0
総利益:	$-4.46M (0.00 %)
EPS:	$-2.30

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.79

Financial Reports:

No articles found.

Kronos Bio, Inc.

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.